and asymmetric forms. [2] [3] [4] [5] [6] [7] [8] The complexity of the diagnosis CIDP in clinical practice is illustrated by the various sets of diagnostic criteria that have been developed for CIDP. [9] [10] [11] But controversy persists about their use in clinical practice and whether these sets of criteria are able to include and discriminate all the CIDP subtypes.
Corticosteroids, intravenous immunoglobulin and plasma exchange are proven effective treatments for CIDP. [12] [13] [14] [15] In general, these treatments have a comparable efficacy, and the treatment in practice primarily depends on the patient's and physician's preferences. The disease course may be either monophasic and not requiring repeated treatments or relapsing-remitting or chronic progressive requiring maintenance treatment. Some patients only respond to one of these treatment types and not to others. At present there are no clinical or biological markers to predict the treatment response or to monitor disease activity in CIDP. In current practice, the treatment of patients with CIDP is largely based on n = 1 experiments. Except for a few proposed treatment algorithms, 16, 17 there is no systematic strategy to optimize maintenance treatment or determine treatment duration and timing of withdrawal attempts. To be able to improve the diagnostic process and treatment of CIDP and understand the pathogenesis of the spectrum of CIDP subtypes, it is required to conduct a prospective study with standardized collection of clinical and electrophysiological data, and biomaterials from a large group of well-defined patients with CIDP during a long follow-up period. For this purpose we started the International CIDP Outcome Study (ICOS) in 2015, which parallels the International GBS Outcome Study in study design and study aims. 18 
| Study aim and objectives
The general aim of the ICOS is to describe the variation in clinical and electrophysiological characteristics of CIDP and to identify the clinical, electrophysiological and biological predictors of disease activity, treatment response and outcome in patients with CIDP. More specifically, the ICOS has the following objectives for CIDP:
1. Describe the clinical phenotypes, define subgroups and improve the diagnostic criteria.
2. Improve outcome measures for treatment response and outcome.
3. Describe the current treatment practice and related clinical outcome.
4. Identify biomarkers for supporting the diagnosis, monitoring of disease activity and prediction of treatment response. and at least two supportive criteria (if not fulfilling the electrophysiological criteria) (Supplement 2).
2. Being able and willing to conduct a follow-up of at least 2 years.
3. Informed consent of the patient or, for children, the parents of legal guardians.
| ICOS data-and biobank
The visits for collecting data and biomaterials are planned every 6 months during a follow-up of at least 2 years ( Figure 1 ). In addition, newly diagnosed CIDP patients will have additional optional visits at 3, 6 and 12 weeks to document the response to treatment.
| Clinical and treatment data
At study entry, data will be collected about the diagnosis, including data obtained during the previous diagnostic work-up, and the clinical situation at the moment of inclusion. 
| Electrophysiology, nerve imaging and other diagnostic data
Nerve conduction studies (NCS) data is important in the diagnostic work-up of CIDP, but not mandatory for participation in ICOS when a patient fulfills additional supportive criteria for CIDP instead (Supplement 2). We collect the results of NCS, including the raw data and local reference values and protocols. NCS can be performed according to the local NCS protocols or via a predefined standard NCS protocol which is provided in Supplement 3. Data on nerve ultrasound, imaging and biopsy and CSF and blood are also collected when performed as part of the routine diagnostic work-up.
| Biomaterials
At study entry blood samples are obtained for the collection of DNA and serum. At every consecutive visit we collect an additional serum sample. Optionally, blood samples can be drawn for isolation of RNA and peripheral blood mononuclear cells in dedicated centers. Preferably blood is drawn pretreatment in newly diagnosed patients. In previously diagnosed patients receiving intravenous immunoglobulins or plasma exchange, blood will be obtained preferably short before a new course of treatment. Blood is stored at the local or the coordinating center. In addition, we collect CSF and material from nerve biopsies, but only if a lumbar puncture or a nerve biopsy is performed as part of the routine diagnostic work-up.
| Data collection
We have developed a web-based data entry system by using the software program OpenClinica. 28 The OpenClinica software meets all standards of the current security and privacy regulations of the Erasmus University Medical Center, the institute that is hosting the data storage. The local investigators use this web-based data entry system to enter the data. In accordance with the privacy regulation the data are stored pseudo-anonymous. Each patient included in ICOS has an unique study code which is used throughout the study.
| Statistical analysis
Descriptive statistics are used to analyze the clinical, diagnostic and treatment data. Various methods will be used to quantify response to treatment, clinical course and outcome. We will calculate proportions, logistic regression and possible survival analysis and develop prognostic models as in previous studies. [29] [30] [31] The association between the putative prognostic factors and the outcome variable will be analyzed using univariable and multivariable logistic regression models. If two similar variables are equally associated with outcome, we will select the variable most easily obtainable in clinical practice. Model performance will be quantified with respect to discrimination (area under receiver operating characteristics curve). The multivariable regression coefficients will be used to develop practical prognostic models in CIDP.
| Sample size
To enable external validation of a predictive logistic regression model, the smallest outcome group should include at least 100 patients. 32 No or an insufficient treatment response to corticosteroids, intravenous immunoglobulins and/or plasma exchange is reported in about 10%-20% of patients, implicating that the total population of patients required is about 500-1000 patients. A change of diagnosis during follow-up is also estimated in 10% of newly diagnosed patients based on previous reports, especially in subjects who do not respond to treatment. 33 To provide a safety margin for patients lost to follow-up, change in diagnosis, testing of multiple panels of potential determinants and for possible influences of geographical or ethnic factors, we aim to include at least 500-1000 newly diagnosed CIDP patients, either in ICOS or in collaboration with other CIDP registries. 
| ICOS CONSORTIUM AND ICOS CLINICAL STUDY AGREEMENT
The ICOS is conducted by the ICOS Consortium which consists of (a) the members of the Steering Committee, (b) the neuromuscular staff of the three coordinating centers, and (c) the local investigators. To be able to participate in ICOS, a Clinical Trial Agreement needs to be signed which defines the conduct of the study and the collaboration.
| Ethical regulations
The was organized on registries in CIDP, attended by 24 researchers from 13 countries. 34 The aim of this meeting was to harmonize existing CIDP registries and to reach consensus on the inclusion and exclusion criteria for future CIDP patients, collection of data and biosamples, and infrastructure for collaboration. We were participating in the ENMC meeting and support the initiative to harmonize CIDP registries for future research. As stated in the report, most participants preferred an infrastructure of one central database which allows local storage of data and biosamples with co-existence of currently ongoing registries that can combine data with the central registry INCbase. 34 the web-based data entry was financially supported by CSL Behring. Further funding was received from the GBS/CIDP foundation, Grifols, the Erasmus MC, Amsterdam UMC, and the UMC Utrecht. ICOS is scientifically independent, the funding by CSL Behring has no influence on the study and the infrastructure, nor on the interpretation and analysis of the data collected in ICOS nor on the publications on these data.
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